To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis

Completed · Phase 1 · Has a placebo group

Conditions studied: Scalp Psoriasis

In brief

To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of scalp psoriasis.

Key facts

Study ID

NCT03880357

Run by

Sun Pharmaceutical Industries, Inc.

People needed

485

Starts

2018-10-22

Expected to finish

2019-03-15

Last updated by the study team

2019-03-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Healthy male or non-pregnant female aged ≥18 years
• All male subjects had to agree to use accepted methods of birth control with their partners, from the day of the first application of the study drug to 30 days after the last application of the study drug
• Willing and able to understand and comply with the requirements of the protocol, including attendance at the required study visits
• A clinical diagnosis of stable (at least 6 months) scalp psoriasis involving at least 10% of the scalp

You may not qualify if…

• Female subjects who were pregnant, nursing, or planning to become pregnant during study participation
• Known hypersensitivity to calcipotriene, betamethasone dipropionate, other corticosteroids, or to any ingredients in the study drugs
• Current diagnosis of unstable forms of psoriasis including guttate, erythrodermic, exfoliative, or pustular psoriasis

Where it is running

• Catawba Research, LLC — Charlotte, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.